LupusTrials.org March 1, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type …
Sign up for our Newsletter
Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.